Motor and non-motor symptoms of 1453 patients with Parkinson's disease: Prevalence and risks

Parkinsonism and Related Disorders

Volumn 19, Issue 8, 2013, Pages 725-731

  Yoritaka, Asako ^a,b   Shimo, Yasushi ^a   Takanashi, Masashi ^a   Fukae, Jiro ^a,c   Hatano, Taku ^a   Nakahara, Toshiki ^a   Miyamato, Nobukazu ^a   Urabe, Takao ^a,d   Mori, Hideo ^a,b   Hattori, Nobutaka ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Juntendo University Hospital   (Japan)

^c FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^d JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

Author keywords

Camptocormia; Natural history studies; Parkinson's disease; Psychosis; Wearing off

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; THREO 3,4 DIHYDROXYPHENYLSERINE; TRIHEXYPHENIDYL; ZONISAMIDE;

AGE DISTRIBUTION; AGED; ANALGESIA; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR;

AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOTOR SKILLS DISORDERS; PARKINSON DISEASE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84879418984     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.04.001     Document Type: Article

References (43)

1. Ben-Shlomo Y., Marmot M.G. Survival and cause of death in a cohort of patients with parkinsonisml: possible clues to aetiology?. JNeurol Neurosurg Psychiatr 1995, 58:293-299.
2. Diem-Zangerl A., Seppi K., Wenning G.K., Trinka E., Ransmayr G., Oberaigner W., et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009, 24:819-825.
3. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatr 1992, 55:181-184.
4. Mckeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of DLB Consortium. Neurology 2005, 65:1863-1872.
5. Frucht S., Rogers J.D., Greene P.E., Gordon M.F., Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908-1910.
6. Ravina B., Marder K., Fernandez H.H., Friedman J.H., McDonald W., Murphy D., et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007, 22:1061-1068.
7. Levenson J.L. Neuroleptic malignant syndrome. Am J Psychiatry 1985, 142:1137-1145.
8. Chaudhuri K.R., Martinez-Martin P., Brown R.G., Sethi K., Stocchi F., Odin P., et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007, 22:1901-1911.
9. Visser M., Verbaan D., van Rooden S.M., Stiggelbout A.M., Marinus J., van Hilten J.J. Assessment of psychiatric complications in Parkinson's disease: the SCOPA-PC. Mov Disord 2007, 22:2221-2228.
10. Marinus J., Visser M., Verwey N.A., Verhey F.R., Middelkoop H.A., Stiggelbout A.M., et al. Assessment of cognition in Parkinson's disease. Neurology 2003, 61:1222-1228.
11. Chung S.J., Jeon S.R., Kim S.R., Sung Y.H., Lee M.C. Bilateral effects of unilateral subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Eur Neurol 2006, 56:127-132.
12. Wright Willis A., Evanoff B.A., Lian M., Criswell S.R., Racette B.A. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 2010, 34:143-151.
13. Linder J., Stenlund H., Forsgren L. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Mov Disord 2010, 25:341-348.
14. Harada H., Nishikawa S., Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol 1983, 40:151-154.
15. Sato K., Hatano T., Yamashiro K., Kagohashi M., Nishioka K., Izawa N., et al. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord 2006, 21:1384-1395.
16. Chaudhuri K.R., Martinez-Martin P., Schapira A.H., Stocchi F., Sethi K., Odin P., et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006, 21:916-923.
17. Negre-Pages L., Regragui W., Bouhassira D., Grandjean H., Rascol O. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008, 23:1361-1369.
18. Beiske A.G., Loge J.H., Ronningen A., Svensson E. Pain in Parkinson's disease: prevalence and characteristics. Pain 2009, 141:173-177.
19. Scott B., Borgman A., Engler H., Johnels B., Aquilonius S.M. Gender differences in Parkinson's disease symptom profile. Acta Neurol Scand 2000, 102:37-43.
20. Barone P., Antonini A., Colosimo C., Marconi R., Morgante L., Avarello T.P., et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009, 24:1641-1649.
21. Martinez-Martin P., Pecurariu C.F., Odin P., van Hilten J.J., Antonini A., Rojo-Abuin J.M., et al. Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. JNeurol 2012, 259:1639-1647.
22. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996, 39:37-45. Parkinson Study Group.
23. Hely M.A., Morris J.G., Reid W.G., Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190-199.
24. Hauser R.A., Rascol O., Korczyn A.D., Jon Stoessl A., Watts R.L., Poewe W., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007, 22:2409-2417.
25. Katzenschlager R., Head J., Schrag A., Ben-Shlomo Y., Evans A., Lees A.J. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008, 71:474-480.
26. Margraf N.G., Wrede A., Rohr A., Schulz-Schaeffer W.J., Raethjen J., Eymess A., et al. Camptocormia in idiopathic Parkinson's disease: a focal myopathy of the paravertebral muscles. Mov Disord 2010, 25:542-551.
27. Spuler S., Krug H., Klein C., Medialdea I.C., Jakob W., Ebersbach G., et al. Myopathy causing camptocormia in idiopathic Parkinson's disease: a multidisciplinary approach. Mov Disord 2010, 25:552-559.
28. Fahn S. Current concept and classification of dystonia. Adv Neurol 1976, 14:177-186.
29. Djaldetti R., Mosberg-Galili R., Sroka H., Merims D., Melamed E. Camptocormia (bent spine) in patients with Parkinson's disease-characterization and possible pathogenesis of an unusual phenomenon. Mov Disord 1999, 14:443-447.
30. Nakayama Y., Miwa H. Drug-induced camptocormia: a lesson regarding vascular parkinsonism. Intern Med 2012, 51:2843-2844.
31. Ondo W.G., Dat Vuong K., Khan H., Atassi F., Kwak C., Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001, 57:1392-1396.
32. Paus S., Brecht H.M., Köster J., Seeger G., Klockgether T., Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003, 18:659-667.
33. Yoritaka A., Ohizumi H., Tanaka S., Hattori N. Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences?. Eur Neurol 2009, 61:164-170.
34. Ghorayeb I., Loundou A., Auquier P., Dauvilliers Y., Bioulac B., Tison F. Anationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Mov Disord 2007, 29:1567-1572.
35. Forsaa E.B., Larsen J.P., Wentzel-Larsen T., Goetz C.G., Stebbins G.T., Aarsland D., et al. A12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010, 67:996-1001.
36. Sanchez-Ramos J.R., Ortoll R., Paulson G.W. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996, 53:1265-1268.
37. Graham J.M., Grunewald R.A., Sagar H.J. Hallucinosis in idiopathic Parkinson's disease. JNeurol Neurosurg Psychiatr 1997, 63:434-440.
38. Barnes J., David A.S. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. JNeurol Neurosurg Psychiatr 2001, 70:727-733.
39. Baker W.L., Silver D., White C.M., Kluger J., Aberle J., Patel A.A., et al. Dopamine agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord 2009, 15:287-294.
40. Hashimoto T., Tokuda T., Hanyu N., Tabata K., Yanagisawa N. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease. Parkinsonism Relat Disord 2003, 9:S25-S30.
41. Takubo H., Harada T., Hashimoto T., Inaba Y., Kanazawa I., Kuno S., et al. Acollaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 2003, 9:S31-S41.
42. Cunnigton A.L., White L., Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. Parkinsonism Relat Disord 2012, 18:1051-1052.
43. Chaudhuri K.R., Prieto-Jurcynska C., Naidu Y., Mitra T., Frades-Payo B., Tluk S., et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010, 25:704-709.